Compare AbbVie Inc (ABBV) vs Herbalife Nutrition Ltd (HLF) Price & Performance

AbbVie (ABBV) trades at $249.9, up 0.8% on the day, with strong analyst support (29 Buy, 1 Sell) and a $278.69 consensus price target. Recent quarterly earnings have consistently beaten estimates, driven by robust immunology drug sales. The stock shows a bullish technical trend, supported by moving averages, and the company maintains solid cash flow and dividend payments.

Outlook is positive with revenue growth and pipeline advancements, though high P/E and debt levels pose risks. The stock offers a compelling buy case for growth and income investors, balanced by execution and patent expiry challenges ahead.

HLF trades at $11.52, down 6.72% in the past 24 hours, with a bearish technical signal and mixed earnings history. The company reported Q2 2026 net sales of $1.3 billion, up 5.4% year-over-year, but missed EPS estimates. Valuation ratios appear attractive with a P/E of 7.53 and P/S of 0.24, though negative shareholder equity and high debt levels remain concerns. Recent news includes a planned CFO transition in December 2026 and inclusion in TIME's America's Best Companies list.

The outlook is cautious due to inconsistent earnings performance and a highly leveraged balance sheet, but low valuation metrics and analyst consensus leaning buy (53.84%) suggest potential upside if operational improvements and debt reduction continue. Key risks include execution challenges, competitive pressures, and sensitivity to macroeconomic conditions.